What happened
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) said 330 patients were randomized in the BACKBEAT Global Pivotal Trial as of September 30, 2026. That is above the company's previously announced target of 316 randomized patients. The trial is evaluating AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite medication. It is being conducted with Medtronic plc, the strategic collaborator for the trial and, subject to regulatory approval, for commercialization of AVIM Therapy in that setting.
The BACKBEAT Trial is global, multi-center, prospective, randomized and double-blind. Patients are randomized 1:1 to AVIM Therapy plus continued medical therapy and pacing or to continued medical therapy and standard pacing alone. The filing says the trial is running at 81 sites across 13 countries.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Randomized patients | 330 patients | from 316 randomized patients, +14 patients | Calculated from SEC 8-K |
| Primary analysis sample | 284 evaluable randomized subjects | Exhibit 99.1 press release | |
| Trial sites | 81 sites | Exhibit 99.1 press release | |
| Countries | 13 countries | Exhibit 99.1 press release | |
| Statistical power | greater than 90% statistical power | Exhibit 99.1 press release | |
| Detection threshold | at least 5 mmHg | Exhibit 99.1 press release |
Why it matters
OptimistFi's case is that partner support can turn clinical programs into milestones and eventual royalties. This filing strengthens that view because the Medtronic-backed BACKBEAT study reached full enrollment. The filing says the protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis. It also says total enrollment was set at 316 patients to account for possible loss to follow-up.
The design is built to detect a between-group difference of at least 5 mmHg in 24-hour ambulatory systolic blood pressure. It has greater than 90% statistical power for both primary endpoints. The 330-patient count gives investors a clear enrollment marker ahead of the readout.
Browse: stock research on every company OptimistFi covers
What's next
Orchestra BioMed and Medtronic intend to submit the primary endpoint results for consideration as a late-breaking clinical trial presentation at a major cardiovascular conference in Q2 2027. The company says those data are expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies.
Orchestra BioMed said it is now focused on completing three-month follow-up, database lock and delivery of a rigorous, well-powered data set next spring. Positive endpoint data would support the regulatory path the filing outlines. The Q2 2027 presentation consideration is the next dated step named in the filing.
More from OptimistFi
- OBIO stock: the Orchestra BioMed thesis, its status and the next test to watch
- Fair Isaac Corporation (NYSE: FICO) Faces Equal Mortgage Pricing
- Broadcom Inc. (NASDAQ: AVGO) Has a $42 Billion Anthropic Test
- Autonomix Medical, Inc. (NASDAQ: AMIX) Gets a Clearer FDA Path
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — Current report on Form 8-K dated October 1, 2026
- Exhibit 99.1 press release — Orchestra BioMed press release announcing BACKBEAT enrollment target exceeded
Read the full OptimistFi thesis on Orchestra BioMed Holdings, Inc.: https://optimistfi.com/stocks/OBIO
See what would break the Orchestra BioMed Holdings, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Orchestra BioMed Holdings, Inc. investment case, its status and the next test to watch live on the Orchestra BioMed Holdings, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
